Venetoclax with azacitidine or decitabine in patients with newly diagnosed acute myeloid leukemia: Long term follow‐up from a phase 1b study
Sign Up to like & getrecommendations! Published in 2020 at "American Journal of Hematology"
DOI: 10.1002/ajh.26039
Abstract: This analysis represents the longest‐term follow‐up for patients with acute myeloid leukemia (AML) treated with 400 mg of venetoclax plus azacitidine or decitabine. Adults with newly diagnosed AML ineligible for intensive chemotherapy were enrolled in an… read more here.
Keywords: newly diagnosed; term follow; myeloid leukemia; venetoclax plus ... See more keywords
Utilization of Hypomethylating Agents and Associated Outcomes in Elderly Acute Myeloid Leukemia (AML) Patients: A Population Based Study
Sign Up to like & getrecommendations! Published in 2017 at "Blood"
DOI: 10.1182/blood.v130.suppl_1.2157.2157
Abstract: Objective: No head to head randomized clinical trial has previously been conducted to compare the clinical outcomes between the hypomethylating agents (HMAs), azacitidine and decitabine, in the treatment of older patients with Acute Myeloid Leukemia… read more here.
Keywords: myeloid leukemia; decitabine; hypomethylating agents; acute myeloid ... See more keywords